Brief: Brii Biosciences Says SARS-CoV-2 Neutralizing Monoclonal Antibody Combination Therapy Demonstrated Statistically Reduction Of 78%
25/08/2021 02:27
Aug 25 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIOSCIENCES -CO'S SARS-COV-2 NEUTRALIZING MONOCLONAL ANTIBODY
COMBINATION
THERAPY DEMONSTRATED A STATISTICALLY REDUCTION OF 78%
* BRII BIOSCIENCES LTD - THERE WERE NO DRUG RELATED SERIOUS ADVERSE EVENTS
OR
DEATHS OBSERVED IN EITHER ARM
Source text for Eikon: ID:
Further company coverage: 2137.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR